GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Trial Data] STEP 1 vs SURMOUNT-1 side by side, with the caveats — 37 comments in the full submission. View in context.
854
c/trialwatch·submitted 7 days ago by u/cesar_ivaturi

[Trial Data] STEP 1 vs SURMOUNT-1 side by side, with the caveats

Trial Databranch of 7 comments

Posting this as a discussion rather than a claim: STEP 1 vs SURMOUNT-1 side by side, with the caveats. Compared myself to a trial mean for about six months before realising the trial arm had dietitian contact every fortnight. Read a press release and the publication three months apart. The hedging in the second one…

Read the full submission and all 37 comments →

This branch

7 comments, started 6 days ago
u/trialwatch_theoMOD61 points·6 days ago

Retitled: the original quoted a diabetes endpoint as an obesity result.

replysharereportpermalink
u/ewan_tulloch48 points·6 days ago

Careful with that mean. The distribution around it was wide enough that it describes very few individual participants.

replysharereportpermalink
u/receipts_or_nothingvetting19 points·6 days ago

This. Intention-to-treat versus completer analysis routinely moves the headline by several points.

replysharereportpermalink
u/cesar_ivaturiOP11 points·6 days ago

What was the discontinuation rate?

replysharereportpermalink
u/enzo_ferrari3 points·5 days ago

SURPASS is the diabetes programme and reports glycaemic endpoints

replysharereportpermalink
u/nils_tulloch2 points·5 days ago

That is the 68-week readout, not the 72-week one. Different trial, different duration.

replysharereportpermalink
u/yusuf_ramos1 point·5 days ago

the appendix is where the interesting tables live

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →